Surrozen (NASDAQ:SRZN) Major Shareholder Acquires $309,226.26 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 12,374 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were acquired at an average cost of $24.99 per share, with a total value of $309,226.26. Following the purchase, the insider directly owned 657,301 shares of the company’s stock, valued at $16,425,951.99. This trade represents a 1.92% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, March 16th, Tcg Crossover Gp Ii, Llc purchased 1,190 shares of Surrozen stock. The stock was bought at an average cost of $24.99 per share, for a total transaction of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc bought 35,433 shares of Surrozen stock. The stock was purchased at an average cost of $24.88 per share, for a total transaction of $881,573.04.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc acquired 1,093 shares of Surrozen stock. The shares were purchased at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The shares were acquired at an average price of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The stock was acquired at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The shares were acquired at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc purchased 4,271 shares of Surrozen stock. The shares were bought at an average price of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Up 1.2%

Shares of Surrozen stock traded up $0.29 on Monday, hitting $25.50. The stock had a trading volume of 33,763 shares, compared to its average volume of 112,361. The stock’s 50-day simple moving average is $23.46 and its two-hundred day simple moving average is $18.20. Surrozen, Inc. has a one year low of $5.90 and a one year high of $29.59. The stock has a market cap of $218.56 million, a price-to-earnings ratio of -1.14 and a beta of 0.53.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SRZN shares. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald initiated coverage on Surrozen in a research report on Thursday, February 19th. They set an “overweight” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Institutional Trading of Surrozen

Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC grew its holdings in shares of Surrozen by 557.1% during the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock valued at $16,301,000 after buying an additional 611,497 shares during the last quarter. Stempoint Capital LP lifted its position in Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Spruce Street Capital LP purchased a new stake in Surrozen during the 4th quarter valued at $9,764,000. Kalehua Capital Management LLC bought a new stake in shares of Surrozen in the 4th quarter worth $8,705,000. Finally, Braidwell LP raised its stake in shares of Surrozen by 235.7% in the fourth quarter. Braidwell LP now owns 470,000 shares of the company’s stock worth $10,622,000 after purchasing an additional 330,000 shares during the last quarter. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.